{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:29:32Z","timestamp":1789673372832,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["cgfr.co.uk","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.cytogfr.2014.01.006","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T12:17:00Z","timestamp":1390997820000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["CXCR3, CXCL10 and type 1 diabetes"],"prefix":"10.1016","volume":"25","author":[{"given":"Alessandro","family":"Antonelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Martina","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alda","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2014.01.006_bib0005","series-title":"Type 1 Diabetes Facts","author":"Juvenile Diabetes Research Foundation","year":"2012"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0010","series-title":"10 facts about diabetes","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0015","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/jama.289.17.2254","article-title":"Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review","volume":"289","author":"DeWitt","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1172\/JCI119878","article-title":"GAD-reactive CD4+ Th1 cells induce diabetes in NOD\/SCID mice","volume":"101","author":"Zekzer","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1172\/JCI8185","article-title":"IL-1\u03b1, IL-1\u03b2, and IFN-\u03b3 mark \u03b2 cells for Fas-dependent destruction by diabetogenic CD4+ T lymphocytes","volume":"105","author":"Amrani","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1900\/RDS.2005.2.182","article-title":"Imbalance in Th cell polarization and its relevance in type 1 diabetes mellitus","volume":"2","author":"Sia","year":"2005","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1468-1331.2003.00638.x","article-title":"Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables","volume":"10","author":"Putheti","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0040","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/bjs.5401","article-title":"Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves\u2019 disease, and modulation by methimazole therapy and thyroidectomy","volume":"93","author":"Antonelli","year":"2006","journal-title":"Br J Surg"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0045","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1210\/jc.2006-1571","article-title":"Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves\u2019 disease or toxic nodular goiter","volume":"92","author":"Antonelli","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0050","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1111\/j.1572-0241.2008.02040.x","article-title":"High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection","volume":"103","author":"Antonelli","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0055","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1210\/jc.2008-2450","article-title":"Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves\u2019 disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"94","author":"Antonelli","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.2009.04813.x","article-title":"CXCR3, inflammation, and autoimmune diseases","volume":"1173","author":"Lacotte","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0065","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2005.09.027","article-title":"Significance of serum CXCL10\/IP-10 level in type 1 diabetes","volume":"26","author":"Shigihara","year":"2006","journal-title":"J Autoimmun"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0070","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.4049\/jimmunol.173.11.7017","article-title":"CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis","volume":"173","author":"Morimoto","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1074\/jbc.M209470200","article-title":"Structure-function relationship between the human chemokine receptor CXCR3 and its ligands","volume":"278","author":"Clark-Lewis","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0080","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1084\/jem.166.4.1084","article-title":"Biochemical characterization of a gamma interferon-inducible cytokine (IP-10)","volume":"166","author":"Luster","year":"1987","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0085","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1084\/jem.187.12.2009","article-title":"Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3","volume":"187","author":"Cole","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0090","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1073\/pnas.87.14.5238","article-title":"A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines","volume":"87","author":"Farber","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0095","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1084\/jem.192.10.1515","article-title":"Requirement of the chemokine receptor CXCR3 for acute allograft rejection","volume":"192","author":"Hancock","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/clim.2000.4957","article-title":"CXCR3 and CCR5 ligands in rheumatoid arthritis synovium","volume":"98","author":"Patel","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1128\/IAI.73.1.485-493.2005","article-title":"CXCR3 and its ligands participate in the host response to Bordetella bronchiseptica infection of the mouse respiratory tract but are not required for clearance of bacteria from the lung","volume":"73","author":"Widney","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0110","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1189\/jlb.68.4.568","article-title":"Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells","volume":"68","author":"Yamamoto","year":"2000","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0115","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/1521-4141(200206)32:6<1792::AID-IMMU1792>3.0.CO;2-0","article-title":"Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR-triggering and requirement for IFN-gamma stimulation","volume":"32","author":"Nakajima","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0120","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.4049\/jimmunol.177.3.1855","article-title":"Both CXCR3 and CXCL10\/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus","volume":"177","author":"Hsieh","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0125","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1128\/JVI.01937-06","article-title":"CXCR3-dependent recruitment of antigen-specific T lymphocytes to the liver during murine cytomegalovirus infection","volume":"81","author":"Hokeness","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1172\/JCI6993","article-title":"Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells","volume":"104","author":"Mach","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0135","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/00007890-200112270-00016","article-title":"Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants","volume":"72","author":"Goddard","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0140","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S","article-title":"Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation","volume":"194","author":"Flier","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0145","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.4049\/jimmunol.169.3.1556","volume":"169","author":"Zhao","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0150","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.194.12.1755","article-title":"Blocking chemokine responsive to gamma-2\/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes","volume":"194","author":"Kakimi","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0155","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1681\/ASN.2007111179","article-title":"CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease","volume":"19","author":"Menke","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.21986","article-title":"CXCL10 regulates liver innate immune response against ischemia and reperfusion injury","volume":"47","author":"Zhai","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0165","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1084\/jem.184.3.963","article-title":"Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes","volume":"184","author":"Loetscher","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0170","doi-asserted-by":"crossref","first-page":"L584","DOI":"10.1152\/ajplung.00453.2003","article-title":"The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells","volume":"287","author":"Kelsen","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0175","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20021897","article-title":"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4","volume":"197","author":"Lasagni","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0180","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.4049\/jimmunol.173.10.6234","article-title":"Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping","volume":"173","author":"Ehlert","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1359-6101(99)00005-2","article-title":"The MCP\/eotaxin subfamily of CC chemokines","volume":"10","author":"Van Coillie","year":"1999","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0190","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.4049\/jimmunol.168.7.3221","article-title":"Secondary lymphoid tissue chemokine (CCL21) activates CXCR3 to trigger a Cl\u2212 current and chemotaxis in murine microglia","volume":"168","author":"Rappert","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0195","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1189\/jlb.1103570","article-title":"I-TAC\/CXCL11 is a natural antagonist for CCR5","volume":"76","author":"Petkovic","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0200","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1471-4159.2008.05267.x","article-title":"Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3","volume":"105","author":"de Jong","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0205","doi-asserted-by":"crossref","first-page":"7417","DOI":"10.4049\/jimmunol.172.12.7417","article-title":"Chemokine monokine induced by IFN-gamma\/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production","volume":"172","author":"Whiting","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/bbrc.1995.1626","article-title":"Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis","volume":"210","author":"Strieter","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0215","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1084\/jem.182.1.155","article-title":"Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo","volume":"182","author":"Angiolillo","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0220","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","article-title":"IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking","volume":"168","author":"Dufour","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0225","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cytogfr.2005.04.007","article-title":"CXC chemokines in angiogenesis","volume":"16","author":"Strieter","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0230","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4049\/jimmunol.167.2.623","article-title":"Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity","volume":"167","author":"Cole","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0235","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/diacare.24.3.510","article-title":"Elevated serum IP-10 levels observed in type 1 diabetes","volume":"24","author":"Shimada","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0240","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00125-002-0879-5","article-title":"Serum concentrations of the interferon-gamma-inducible chemokine IP-10\/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease","volume":"45","author":"Nicoletti","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0245","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1196\/annals.1288.059","article-title":"Two cases of \u201cfulminant\u201d type 1 diabetes suggesting involvement of autoimmunity","volume":"1005","author":"Nakagawa","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0250","first-page":"853","article-title":"The changes of serum interferon-inducible protein-10 levels in children with type 1 diabetes mellitus","volume":"45","author":"Xin","year":"2007","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0255","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1464-5491.2008.02577.x","article-title":"Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study","volume":"25","author":"Antonelli","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0260","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2249.2010.04193.x","article-title":"Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis","volume":"161","author":"Kaas","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0265","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.2011.04538.x","article-title":"Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients","volume":"168","author":"Gabbay","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0270","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s00125-003-1134-4","volume":"46","author":"Rotondi","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0275","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1464-5491.2005.01743.x","article-title":"Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus","volume":"23","author":"Hanifi-Moghaddam","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0280","doi-asserted-by":"crossref","first-page":"31212","DOI":"10.1074\/jbc.M602445200","article-title":"Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b","volume":"281","author":"Shanmugam","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0285","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cyto.2009.02.004","article-title":"Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway","volume":"47","author":"Devaraj","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/dmrr.1052","article-title":"Ex vivo TCR-induced leukocyte gene expression of inflammatory mediators is increased in type 1 diabetic patients but not in overweight children","volume":"26","author":"Rosa","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0295","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humimm.2009.04.031","article-title":"Polymorphisms of CXCR3-binding chemokines in type 1 diabetes","volume":"70","author":"Br\u00fcck","year":"2009","journal-title":"Hum Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0300","first-page":"10","article-title":"Effect of the IP10 (CXCL10) and HLA genotype on the risk of type 1 diabetes in children","volume":"17","author":"Klich","year":"2011","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0305","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm1202-792","article-title":"Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis","volume":"8","author":"Frigerio","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0310","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2249.2009.04087.x","article-title":"Islet inflammation and CXCL10 in recent-onset type 1 diabetes","volume":"159","author":"Roep","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0315","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00125-010-1849-y","article-title":"Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients","volume":"53","author":"Pugazhenthi","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0320","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1507\/endocrj.K10E-076","article-title":"Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes","volume":"57","author":"Uno","year":"2010","journal-title":"Endocr J"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0325","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2337\/db11-0853","article-title":"Expression and regulation of chemokines in murine and human type 1 diabetes","volume":"61","author":"Sarkar","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0330","doi-asserted-by":"crossref","first-page":"e55071","DOI":"10.1371\/journal.pone.0055071","article-title":"The kinetics of plasmacytoid dendritic cell accumulation in the pancreas of the NOD mouse during the early phases of insulitis","volume":"8","author":"Welzen-Coppens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0335","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.4049\/jimmunol.171.12.6838","article-title":"Among CXCR3 chemokines, IFN-gamma-inducible protein of 10kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease","volume":"171","author":"Christen","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0340","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1172\/JCI17005","article-title":"Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient","volume":"113","author":"Christen","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0345","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/08916930410001713124","article-title":"IP-10 and type 1 diabetes: a question of time and location","volume":"37","author":"Christen","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0350","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.2337\/db12-1370","article-title":"Functional redundancy of CXCR3\/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model","volume":"62","author":"Coppieters","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0355","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/db09-0091","article-title":"Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes","volume":"58","author":"Tanaka","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0360","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/jmv.21868","article-title":"Enterovirus markers and serum CXCL10 in children with type 1 diabetes","volume":"82","author":"Berg","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0365","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/jmv.21900","article-title":"Enterovirus infection induces cytokine and chemokine expression in insulin-producing cells","volume":"82","author":"Nair","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0370","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/jmv.21924","article-title":"Modulation of innate immunity in human pancreatic islets infected with enterovirus in vitro","volume":"83","author":"Skog","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0375","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/jmv.21476","article-title":"Antiviral effect of nicotinamide on enterovirus-infected human islets in vitro: effect on virus replication and chemokine secretion","volume":"81","author":"Mo\u00ebll","year":"2009","journal-title":"J Med Virol"},{"issue":"November","key":"10.1016\/j.cytogfr.2014.01.006_bib0380","article-title":"Infection of human islets of langerhans with two strains of coxsackie B virus serotype 1: assessment of virus replication, degree of cell death and induction of genes involved in the innate immunity pathway","author":"Anagandula","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0385","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.3390\/molecules18043841","article-title":"Phenylmethimazole suppresses dsRNA-induced cytotoxicity and inflammatory cytokines in murine pancreatic beta cells and blocks viral acceleration of type 1 diabetes in NOD mice","volume":"18","author":"McCall","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0390","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2249.2011.04426.x","article-title":"Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model","volume":"165","author":"Christen","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0395","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jdiacomp.2006.01.001","article-title":"Hepatitis C infection and diabetes","volume":"20","author":"Noto","year":"2006","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0400","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/rheumatology\/keh011","article-title":"Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients","volume":"43","author":"Antonelli","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0405","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.2337\/diacare.28.10.2548","article-title":"Hepatitis C virus infection: evidence for an association with type 2 diabetes","volume":"28","author":"Antonelli","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0410","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-133-8-200010170-00009","article-title":"Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States","volume":"133","author":"Mehta","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0415","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/jhep.2003.50291","article-title":"Hepatitis C virus infection and incident type 2 diabetes","volume":"38","author":"Mehta","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0420","first-page":"335","article-title":"Changes in glucose tolerance after interferon-alpha therapy in ptients with chronic hepatitis C","volume":"28","author":"Tanaka","year":"1997","journal-title":"J Med"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0425","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1111\/j.1572-0241.2008.02002.x","article-title":"Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study","volume":"103","author":"Giordanino","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0430","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2337\/diacare.28.4.940","article-title":"Hepatitis C virus infection and human pancreatic beta-cell dysfunction","volume":"28","author":"Masini","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0435","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00125-005-1954-5","article-title":"Latent autoimmune diabetes in adults: a guide for the perplexed","volume":"48","author":"Gale","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0440","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2337\/diacare.29.03.06.dc05-2263","article-title":"Hepatitis C virus infection: evidence for an association with type 2 diabetes: response to Antonelli et al","volume":"29","author":"Skowro\u0144ski","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0445","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s00125-002-0886-6","article-title":"Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes","volume":"45","author":"Antonelli","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0450","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2337\/diabetes.50.5.985","article-title":"Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets","volume":"50","author":"Antonelli","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0455","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2893.2005.00540.x","article-title":"Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins","volume":"12","author":"Apolinario","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0460","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.autrev.2008.07.017","article-title":"Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia","volume":"8","author":"Antonelli","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.cytogfr.2014.01.006_bib0465","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1590-8658(07)80005-3","article-title":"HCV-related autoimmune and neoplastic disorders: the HCV syndrome","volume":"39","author":"Ferri","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0470","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cyto.2012.11.008","article-title":"Antibodies recognizing specific Mycobacterium avium subsp. paratuberculosis's MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine","volume":"61","author":"Cossu","year":"2013","journal-title":"Cytokine"},{"issue":"November","key":"10.1016\/j.cytogfr.2014.01.006_bib0475","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","author":"Antonelli","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0480","doi-asserted-by":"crossref","first-page":"8401","DOI":"10.4049\/jimmunol.175.12.8401","article-title":"CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell proliferation in NOD mice","volume":"175","author":"Shigihara","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0485","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/0891693031000079266","article-title":"Assessment of beta cell mass and oxidative peritoneal exudate cells in murine type 1 diabetes using adoptive transfer system","volume":"36","author":"Yamada","year":"2003","journal-title":"Autoimmunity"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0490","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.imbio.2012.07.018","article-title":"1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism","volume":"217","author":"Korf","year":"2012","journal-title":"Immunobiology"},{"issue":"October","key":"10.1016\/j.cytogfr.2014.01.006_bib0495","article-title":"St. John's wort extract and hyperforin protect rat and human pancreatic islets against cytokine toxicity","author":"Novelli","year":"2013","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.cytogfr.2014.01.006_bib0500","doi-asserted-by":"crossref","first-page":"e56924","DOI":"10.1371\/journal.pone.0056924","article-title":"Inhibition of nuclear factor-\u03baB activation in pancreatic \u03b2-cells has a protective effect on allogeneic pancreatic islet graft survival","volume":"8","author":"Eldor","year":"2013","journal-title":"PLoS One"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610114000070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610114000070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:13:49Z","timestamp":1716491629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610114000070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1359610114000070"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2014.01.006","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCR3, CXCL10 and type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2014.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}